Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor

American Journal of Pathology

Volumn 156, Issue 3, 2000, Pages 1033-1039

  Mulligan, Michael S ^a   Lentsch, Alex B ^b   Huber Lang, Markus ^a   Guo, Ren Feng ^a   Sarma, Vidya ^a   Wright, Clifford D ^c   Ulich, Thomas R ^c   Ward, Peter A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b University of Louisville School of Medicine   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHYMOTRYPSIN; ELASTASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SERINE PROTEINASE; TRYPSIN;

ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD VESSEL PERMEABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; IMMUNOGLOBULIN DEPOSITION; NEUTROPHIL; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RAT;

EID: 0033871521     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64971-1     Document Type: Article

References (30)

1. Functional studies of human secretory leukocyte protease inhibitor
2. Human mucus proteinase inhibitor (human MPI), Human seminal inhibitor I (HUSI-I), antileukoprotease (ALP), secretory leukocyte protease inhibitor (SLPI)
3. Secretory leukocyte protease inhibitor: A macrophage product induced by and antagonistic to bacterial lipopolysaccharide
4. Secretory leukocyte protease inhibitor: A human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro
5. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription
6. In vivo suppression of immune complex-induced alveolitis by secretory leukoproteinase inhibitor and tissue inhibitor of metattoproteinases 2
7. Role of complement, chemokines, and regulatory cytokines in acute lung injury
8. Inhibition of NF-κB activation and augmentation of IκBβ by secretory leukocyte protease inhibitor during lung inflammation
9. Location of the protease-inhibitory region of secretory leukocyte protease inhibitor
10. A one-hour minipreparation technique for extraction of DNA-binding proteins from animal tissues
11. L-Pyrogtutamyl-L-crolyl-L-valine-p-nitroanilide: A highly specific substrate for granulocyte elastase
12. The action of trypsin on synthetic chromogenic arginine substrates
13. A sensitive new substrate for chymotrypsin
14. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase
15. Acute immunologic pulmonary alveolitis
16. In vivo suppression of NF-κB and preservation of IκBα by interleukin-10 and interleukin-13
17. Isolation and properties of human plasma α1-proteinase inhibitor
18. The interaction of a-1-antitrypsin with chymotrypsin, trypsin and elastase
19. Extracellular activities of human granzyme A: Monocyte activation by granzyme A versus α-thrombin
20. C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils
21. Requirement and role of C5a in acute lung inflammatory injury in rats
22. In vitro and in vivo dependency of chemokine generation on C5a and TNF-α
23. Comparative effect of C3a and C5a on adhesion molecule expression on neutrophils and endothelial cells
24. Protective effects of an aptamer inhibitor of neutrophil elastase in lung inflammatory injury
25. Essential role of alveolar macrophages in intrapulmonary activation of NF-κB
26. NF-κB activation during IgG immune complex-induced lung injury: Requirements for TNF-α and IL-1β but not complement
27. In vivo antioxidant treatment suppresses nuclear factor-κB activation and neutrophilic lung inflammation
28. NF-κB, and Rel proteins: Evolutionadly conserved mediators of immune responses
29. Effect of proteasome inhibitors on monocytic IκB-α and -β depletion, NF-κB activation, and cytokine production
30. The multicatalytic proteinase: Multiple proteolytic activities